20 May 2022 , 02:17 PM
Net profit of Zydus Lifesciences declined 46.87% to Rs 246.90 crore in the quarter ended March 2022 as against Rs 464.70 crore during the previous quarter ended March 2021. Sales declined 1.56% to Rs 1919.20 crore in the quarter ended March 2022 as against Rs 1949.70 crore during the previous quarter ended March 2021. For the full year,net profit declined 41.88% to Rs 857.90 crore in the year ended March 2022 as against Rs 1476.20 crore during the previous year ended March 2021. Sales rose 2.06% to Rs 7590.00 crore in the year ended March 2022 as against Rs 7436.70 crore during the previous year ended March 2021.
| Particulars | Quarter Ended | Year Ended | ||||
| ? | Mar. 2022 | Mar. 2021 | % Var. | Mar. 2022 | Mar. 2021 | % Var. |
| Sales | 1919.20 | 1949.70 | -2 | 7590.00 | 7436.70 | 2 |
| OPM % | 23.84 | 30.46 | – | 25.27 | 31.04 | – |
| PBDT | 469.30 | 556.80 | -16 | 1961.90 | 2327.10 | -16 |
| PBT | 346.50 | 441.80 | -22 | 1483.20 | 1876.00 | -21 |
| NP | 246.90 | 464.70 | -47 | 857.90 | 1476.20 | -42 |
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
